Merck, Moderna claim encouraging melanoma vaccine trial results
Merck and Moderna announced that their personalized mRNA vaccine, intismeran, combined with Keytruda, reduced recurrence and spread of melanoma in a late-stage trial, the first positive Phase 3 result for an mRNA-based cancer therapy. Shares of Moderna more than doubled, while Merck also gained, as the companies prepare to discuss regulatory filings.